G1359A Polymorphism in the Cannabinoid receptor-1 gene is associated with the presence of coronary artery disease in patients with type 2 diabetes

Journal of Investigative Medicine

Volumn 60, Issue 1, 2012, Pages 44-48

  Wang, Rui ^a   Hu, Wenchao ^b   Qiang, Lu ^c  

^a Tanggu Blood Center   (China)

^b Medical University   (China)

^c BEIJING UNIVERSITY OF CHINESE MEDICINE THIRD AFFILIATED HOSPITAL   (China)

Author keywords

Cannabinoid receptor 1; Coronary artery disease; Polymorphism; Type 2 diabetes

Indexed keywords

C REACTIVE PROTEIN; CANNABINOID 1 RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BODY MASS; CHINESE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; FEMALE; GENETIC RISK; GENOTYPE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SYSTOLIC BLOOD PRESSURE;

ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHINA; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; ETHNIC GROUPS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, CANNABINOID, CB1;

EID: 84863073765     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e31823d79a4     Document Type: Article

References (23)

1. Viveros MP, de Fonseca FR, Bermudez-Silva FJ, et al. Critical role of the endocannabinoid system in the regulation of food intake and energy metabolism, with phylogenetic, developmental, and pathophysiological implications. Endocr Metab Immune Disord Drug Targets. 2008;8: 220-230.
2. de Luis DA, González Sagrado M, Aller R, et al. Influence of G1359A polymorphism of the cannabinoid receptor gene on anthropometric parameters and insulin resistance in women with obesity. Metabolism. 2011;60: 272-276.
3. Baye TM, Zhang Y, Smith E, et al. Genetic variation in cannabinoid receptor 1 (CNR1) is associated with derangements in lipid homeostasis, independent of body mass index. Pharmacogenomics. 2008;9: 1647-1656.
4. Luis DA, González Sagrado M, Aller R, et al. G1359A polymorphism of the cannabinoid receptor gene (CNR1) on anthropometric parameters and cardiovascular risk factors in patients with morbid obesity. Nutr Hosp. 2009;24: 688-692.
5. Singh S, Dhingra S, Ramdath DD, et al. Risk factors preceding type 2 diabetes and cardiomyopathy. J Cardiovasc Transl Res. 2010;3: 580-596.
6. Ahlqvist E, Ahluwalia TS, Groop L. Genetics of type 2 diabetes. Clin Chem. 2011;57: 241-254.
7. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation. 1979;59: 8-13. (Pubitemid 9082394)
8. Moss SE, Klein R, Klein BE. Cause-specific mortality in a population-based study of diabetes. Am J Public Health. 1991;81: 1158-1162.
9. Scheen AJ. The endocannabinoid system: a promising target for the management of type 2 diabetes. Curr Protein Pept Sci. 2009;10: 56-74.
10. + oscillation in islet beta-cells via CB1 receptors. Regul Pept. 2008;145: 49-53. (Pubitemid 350296356)
11. Kim W, Doyle ME, Liu Z, et al. Cannabinoids inhibit insulin receptor signaling in pancreatic {beta}-cells. Diabetes. 2011;60: 1198-1209.
12. Hollander PA, Amod A, Litwak LE, et al. Effect of rimonabant on glycemic control in insulin-treated type 2 diabetes: the ARPEGGIO trial. Diabetes Care. 2010;33: 605-607.
13. Prudente S, Morini E, Trischitta V. Insulin signaling regulating genes: effect on T2DM and cardiovascular risk. Nat Rev Endocrinol. 2009;5: 682-693.
14. Padmanabhan S, Hastie C, Prabhakaran D, et al. Genomic approaches to coronary artery disease. Indian J Med Res. 2010;132: 567-578.
15. Nissen SE, Nicholls SJ, Wolski K, et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA. 2008;299: 1547-1560. (Pubitemid 351482794)
16. Rajesh M, Mukhopadhyay P, HaskóG, et al. Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells. Br J Pharmacol. 2010;160: 688-700.
17. Gazzerro P, Caruso MG, Notarnicola M, et al. Association between cannabinoid type-1 receptor polymorphism and body mass index in a southern Italian population. Int J Obes (Lond). 2007;31: 908-912. (Pubitemid 46842680)
18. Hu WC, Feng P. G1359A polymorphism in the cannabinoid receptor-1 gene is associated with metabolic syndrome in the Chinese Han population. Arch Med Res. 2010;41: 378-382.
19. de Luis DA, González Sagrado M, Aller R, et al. Relation of G1359A polymorphism of the cannabinoid receptor (CB1) gene with metabolic syndrome by ATP III classification. Diabetes Metab Res Rev. 2011;27: 506-511.
20. De Luis DA, González Sagrado M, Aller R, et al. Roles of G1359A polymorphism of the cannabinoid receptor gene (CNR1) on weight loss and adipocytokines after a hypocaloric diet. Nutr Hosp. 2011;26: 317-322.
21. de Luis DA, Pacheco D, Aller R, et al. G 1359A polymorphism of the cannabinoid receptor gene (CNR1) and clinical results of biliopancreatic diversion. Eur Rev Med Pharmacol Sci. 2010;14: 197-201.
22. de Luis DA, González Sagrado M, Aller R, et al. G1359A polymorphism of the cannabinoid receptor gene (CNR1) and insulin resistance in patients with diabetes mellitus type 2. Nutr Hosp. 2010;25: 34-38.
23. Després JP, Ross R, Boka G, et al. Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Arterioscler Thromb Vasc Biol. 2009;29: 416-423.